Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by MacrophagesVimseltinib is a Selective CSF1R Inhibitor for TGCT

Overview of attention for article published in Molecular Cancer Therapeutics, August 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

twitter: 7 X users

Citations

dimensions_citation: 30 Dimensions

Readers on

mendeley: 18 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 9 X posts from 7 X users, with an upper bound of 7,079 followers.

RRIDs were included in the Molecular Cancer Therapeutics paper "Vimseltinib: A Precision CSF1R Therapy for Tenosyn…" (https://t.co/KX0JnYk37b). Thank you for making your #methodsmatter. #ReproducibleResearch

13 Jan 2023

Reply Repost Favourite

Myeloid cells can promote tumorigenesis making them a rational therapeutic target. This #FirstDisclosure paper the development of new CSF1R inhibitor vimseltinib and shows that it reduces tumor burden in patients with #TenosynovialGiantCellTumors. https://

12 Apr 2022

Reply Repost Favourite

#FirstDisclosure Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages https://t.co/7rq5UTMFai https://t.co/9zDS6TSfWC

17 Nov 2021

Reply Repost Favourite

#FirstDisclosure Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages https://t.co/pQcCYX7Ngb https://t.co/VMc4ocCGU4

04 Nov 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.